Bellus Health Inc

BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BELLUS Health is focused on developing drugs for rare diseases, starting with conditions that affect the kidneys. The lead program KIACTA™, a novel drug candidate, is in data review after announcing on June 20, 2016 top-line results from its Phase 3 study for the treatment of AA amyloidosis, a rare disease resulting in renal dysfunction that often leads to dialysis and death. BELLUS Health is partnered with global private equity firm Auven Therapeutics for the development of KIACTA™. KIACTA™ is also being developed as a treatment in a second indication called sarcoidosis, a rare, potentially fatal inflammatory condition that affects the lungs. An investigational new drug application (IND) for a Phase 2/3 clinical study is expected to be filed with the U.S. Food and Drug Administration in 2016. In addition, BELLUS Health is developing Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli (sHUS). sHUS often leads to dialysis, chronic kidney disease and in some cases death, particularly in children. Shigamab™ pre-clinical studies for the treatment of sHUS are currently underway.  BELLUS Health’s pipeline also includes a research-stage project for the treatment of AL amyloidosis, a rare disease in which amyloid protein builds up and causes dysfunction in various parts of the body.

LOS ANGELES--(BUSINESS WIRE)---- $BLU #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired BELLUS Health Inc. (“BELLUS” or the “Company”) (NASDAQ: BLU) securities between September 5, 2019 and July 5, 2020, inclusive (the “Class Period”). BELLUS investors have until May 17, 2021 to file a lead plaintiff motion. If you suffered a loss on your BELLUS investme

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of BELLUS Health Inc. (BLU) Investors

New York, New York--(Newsfile Corp. - March 19, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of BELLUS Health Inc. (NASDAQ: BLU) between September 5, 2019 and July 5, 2020, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court...

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages BELLUS Health Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BLU

BENSALEM, Pa.--(BUSINESS WIRE)---- $BLU #CLASSACTION--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased BELLUS Health Inc. (“BELLUS” or the “Company”) (NASDAQ: BLU) securities between September 5, 2019 and July 5, 2020, inclusive (the “Class Period”). BELLUS investors have until May 17, 2021 to file a lead plaintiff motion. Investors suffering losses on their BELLUS investments are encouraged to contact the Law Offices of Howard G. Smith to discu

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of BELLUS Health Inc. (BLU) Investors

Los Angeles, California--(Newsfile Corp. - March 19, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against BELLUS Health Inc. (NASDAQ: BLU) ("BELLUS" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between September 5, 2019 and July 5, 2020, inclusive...

INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against BELLUS Health Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES, March 18, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against BELLUS Health Inc. ("BELLUS" or "the Company") (NASDAQ: BLU) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 5, 2019 and July 5, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before May 17, 2021.

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against BELLUS Health Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $BLU #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of BELLUS Health Inc. (“BELLUS” or the “Company”) (NASDAQ: BLU) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your BELLUS investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws,

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of BELLUS Health Inc. (BLU) on Behalf of Investors

NEW YORK, March 17, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of BELLUS Health Inc. (NASDAQ: BLU) between September 5, 2019 and July 5, 2020, inclusive (the "Class Period"). A class action lawsuit has already been filed.

INVESTOR NOTICE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages BELLUS Health Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline - BLU

NEW YORK--(BUSINESS WIRE)-- #BellusHealth--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of investors that purchased Bellus Health, Inc. (NASDAQ: BLU) securities between September 5, 2019 and July 5, 2020, inclusive (the “Class Period”). Investors have until May 17, 2021 to apply to the Court to be appointed as lead plaintiff in the law

BELLUS HEALTH ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Bellus Health, Inc. and Encourages Investors to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $BLU #investors--The Law Offices of Frank R. Cruz Announces Investigation of BELLUS Health Inc. (BLU) on Behalf of Investors

The Law Offices of Frank R. Cruz Announces Investigation of BELLUS Health Inc. (BLU) on Behalf of Investors

Los Angeles, California--(Newsfile Corp. - March 17, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against BELLUS Health Inc. ("BELLUS" or "the Company") (NASDAQ: BLU) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between September 5, 2019 and July 5, 2020,...

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against BELLUS Health Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

BENSALEM, Pa.--(BUSINESS WIRE)---- $BLU #CLASSACTION--Law Offices of Howard G. Smith announces an investigation on behalf of BELLUS Health Inc. (“BELLUS” or the “Company”) (NASDAQ: BLU) investors concerning the Company's possible violations of federal securities laws. BELLUS is a clinical-stage biopharmaceutical company whose lead product is BLU-5937, which is being developed for the treatment of chronic cough and other afferent hypersensitization-related disorders. On July 6, 2020, before the market opened, BELLUS

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of BELLUS Health Inc. (BLU) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)---- $BLU #BLU--SHAREHOLDER ACTION ALERT: The Schall Law Firm Files Class Action Suit Against BELLUS Health Inc.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Files Class Action Suit Against BELLUS Health Inc.

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of BELLUS Health Inc. (NASDAQ: BLU) between September 5, 2019 and July 5, 2020, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 17, 2021. SO WHAT: If you purchased BELLUS securities during the Class Period you may

BLU BREAKING NEWS: ROSEN, A TOP RANKED LAW FIRM, Encourages BELLUS Health Inc. Investors to Secure Counsel Before Important Deadline – BLU

LOS ANGELES--(BUSINESS WIRE)---- $BLU #BLU--The Schall Law Firm Files Class Action Suit Against BELLUS Health Inc.

The Schall Law Firm Files Class Action Suit Against BELLUS Health Inc.

Athenex

Catalyst Pharmaceuticals

New Age Beverages

OPKO Health

Spectrum Pharma

Uranium Energy

These penny stocks have more than just a low price point. They have Wall Street analysts backing up those prices with high price targets.

7 Penny Stocks That Wall Street Thinks Are Undervalued

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today reported its financial and operating results for the year ending December 31, 2020. “Over the past 12 months, we have made significant progress with our corporate strategy, financial position, and clinical development of BLU-593

BELLUS Health Reports Year 2020 Financial Results and Business Highlights

ObsEva

Penny stocks like BLU stock and OBSV stock are gaining traction with retail investors, especially as analyst sentiment heats up. The post Penny Stocks News: Why Little-Known Plays OBSV and BLU Are Climbing Today appeared first on InvestorPlace.

Penny Stocks News: Why Little-Known Plays OBSV and BLU Are Climbing Today

Bellus (BLU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Bellus Health (BLU) Report Negative Q4 Earnings? What You Should Know

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced that Dr. Catherine Bonuccelli, M.D., BELLUS Health's Chief Medical Officer, and Dr. Denis Garceau, Ph.D., Bellus Health's Senior Vice President of Drug Development, will be presenting data on BLU-5937 at the

BELLUS Health to Present at the Eleventh International Virtual Cough Symposium

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), announces that it has entered today into an agreement (the “Sales Agreement”) with Jefferies LLC ("Jefferies") pursuant to which the Company may from time to time in the future sell, through at-the-market distributions with Jefferies acting as sales agent, such common shares as would have an aggregate offer price of up to US$50.0 million, including sales made directly on the Nasdaq Globa

BELLUS Health Establishes At-the-Market Facility

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that the first patient has been dosed in the Phase 2 BLUEPRINT trial of BLU-5937, the Company's highly selective P2X3 antagonist, in patients with chronic pruritus associated with atopic dermatitis. “The initiation of

BELLUS Health Announces First Patient Dosed in its Phase 2 BLUEPRINT Trial of BLU-5937 for the Treatment of Chronic Pruritus Associated with Atopic Dermatitis

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that the first patient has been dosed in the Phase 2b SOOTHE trial of BLU-5937, the Company's highly selective P2X3 antagonist, in patients with refractory chronic cough. “We are thrilled to announce the initiation of

BELLUS Health Announces First Patient Dosed in its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced the appointment of Ramzi Benamar to the role of Chief Financial Officer. Mr. Benamar is a seasoned financial executive, bringing over two decades of biopharmaceutical expertise to the position. “We are excited to welco

BELLUS Health Appoints Ramzi Benamar as Chief Financial Officer

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will participate in a fireside chat at the Evercore ISI 3rd Annual Virtual HealthCONx Conference. Presentation Details: Event: Evercore ISI 3

BELLUS Health to Participate in the Evercore ISI 3rd Annual Virtual HealthCONx Conference

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today reported its financial and operating results for the third quarter ended September 30, 2020. “We are pleased with the progress we have made over the last few months, completing key steps required to advance our development plans

News for Bellus Health Inc Stock (BLU)